Oncoinvent achieves 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin®

/in

Strong recruitment momentum demonstrated in 2026 Year-to-date recruitment has already surpassed total enrollment for 2025 Oslo, Norway, 18 June 2026: Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that its ongoing Phase 2 trial of […]

Read more

Christian Wichert appointed Chief Executive Officer to lead next phase of growth

/in

Senior executive across industrial biotechnology and consumer markets with strong expertise in commercialization joins AMSilk as the Company advances from development through scale-up to market growth The announcement follows the launch of biotech silk protein yarns in Balenciaga Spring 2026 collection Neuried, Germany, June 17, 2026 – AMSilk GmbH (“AMSilk”), a global leader in advanced […]

Read more

Resolution Therapeutics extends inflammatory and fibrotic disease pipeline with in vivo Regenerative Macrophage Therapy

/in

Material Transfer Agreements provide access to leading lipid nanoparticle formulations to validate delivery of its proprietary payloads and accelerate development of in vivo Regenerative Macrophage Therapy  Development programme complements Company’s autologous engineered Regenerative Macrophage Therapy, RTX001, in Ph 1/2 clinical development Together, programmes aim to broaden patient population able to benefit from Regenerative Macrophage Therapy  […]

Read more

Poolbeg Pharma plc – Decision to grant European Patent received for POLB 001 in cancer immunotherapy-induced CRS

/in

Major milestone will provide IP protection in key European markets, strengthening global patent portfolio 16 June 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has received formal notification of the decision to grant for its POLB 001 cancer immunotherapy-induced […]

Read more

Hansa Biopharma appoints Adam Cutler as new Chief Financial Officer

/in

Lund, Sweden, 15 June 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) announced today the appointment of Adam Cutler as Chief Financial Officer (CFO) and a member of the Executive Committee, effective June 22, 2026.  Adam succeeds Evan Ballantyne, who has served as CFO since 2024. Evan will continue in the role until June 22 […]

Read more
© Optimum Strategic Communications.